LifeTree eClinical to Manage Clinical Study for Weight Loss Medication
Posted on: Thursday, 15 March 2007, 18:00 CDT
TEMECULA, Calif., March 15 /PRNewswire/ -- LifeTree eClinical, a member of the FFF Enterprises Inc. family of companies and a leading provider of clinical electronic data capture and analysis systems, today announced the company has been awarded a contract for a clinical study to determine the safety, tolerability, pharmacokinetic and pharmacodynamic properties of a powder-form of a weight loss medication.
The three-part study aims to determine the effects of a maximum tolerated dose of the medication in obese subjects.
"The Centers for Disease Control and Prevention estimates that 66 percent of the U.S. adult population is overweight or obese!" said Patrick M. Schmidt, president and CEO of LifeTree and FFF Enterprises. "We believe it is important for us to assist with clinical studies that may aid in the improvement of this national problem."
According to the CDC, being overweight or obese increases the risk of many diseases and health conditions, including Type 2 diabetes, coronary heart disease, stroke and osteoarthritis, to name a few.
About LifeTree eClinical
LifeTree eClinical is a member of the FFF Enterprises Inc. family of companies, headquartered in Temecula, California. The LifeTree suite of clinical technologies and services has been used in Phase I through IV trials, patient registries and diagnostic and epidemiological studies. The LifeTree ICTM component of the LifeTree eClinical suite provides tools for clinical study design, data entry and data reporting. The suite is completely workflow driven and contains extensive clinical trial metrics and trial management tools that are built-in for designated roles within the clinical trial process. SAS data on demand and a complete menu for building data reports fully empower a study's data analyst. The clinical data is fully audit trailed, and it is CDISC- and 21 CFR Part 11-compliant. For more information, call 800-211-2799 ext 1358, email info@lifetree-tech.com or visit http://www.lifetreeclinical.com/.
Contact: K-B Gressitt VP of Communications P: 800-843-7477 x 1143 C: 760-522-1064
LifeTree eClinical
CONTACT: K-B Gressitt, VP of Communications of LifeTree eClinical,+1-800-843-7477, ext. 1143, or cell, +1-760-522-1064
Web site: http://www.lifetreeclinical.com/
Source: PRNewswire
Related Articles
- Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
- Nymox Announces New Clinical Data From BPH Drug Trials to Be Presented at Upcoming U.S. Urology Meeting
- Vion Pharmaceuticals Presents Clinical Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML Patients With Unfavorable Cytogenetics at EHA Meeting
- NeurogesX Announces Presentation of Positive Phase 3 Clinical Data at the Second International Congress on Neuropathic Pain Meeting (NeuPSIG)
- Vion Pharmaceuticals Presents Updated Clinical Data From a Phase II Trial of Cloretazine(R) (VNP40101M) in Patients With Relapsed or Refractory Small Cell Lung Cancer
- Pharmos Announces Clinical Data From Phase 2a Trial of Cannabinor for Capsaicin-Induced Pain
- Rita Medical Highlights Recent Clinical Data Updating Study of Radiofrequency Ablation in the Treatment of Breast Cancer
- Advanced Life Sciences to Present Clinical Data on Selected Cethromycin Trials at the Infectious Diseases Society of America 44th Annual Meeting
- Clinical Data and Duke University in Pharmacogenomics Research and Commercialization Collaboration
- InterMune Announces Presentation of Clinical Data From Studies of Daily Infergen With and Without Ribavirin for the Treatment of HCV
 |
 |
User Comments (0)
RSS Feeds